Lärkberget (LARK) Q4 2024 earnings summary

Executive summary

• Strategic review led to discontinuation of all research operations and termination of all employees, including the CEO, to maximize shareholder value.

• Board is now focused on evaluating new investment opportunities, collaborations, or acquisitions, with a potential dividend if no attractive alternatives are found.

• Company maintains a strong cash position post-restructuring, with SEK 58–63 million available after liquidation costs.

Financial highlights

• Net sales for Jan–Dec 2024 were SEK 326 thousand, down from SEK 5,544 thousand year-over-year, due to the end of the Spark Therapeutics collaboration.

• Operating result for Jan–Dec 2024 was SEK -47,218 thousand, compared to SEK -38,600 thousand in 2023.

• Net loss for Jan–Dec 2024 was SEK -44,878 thousand, versus SEK -35,665 thousand in 2023.

• Cash and cash equivalents at year-end were SEK 73,748 thousand, down from SEK 101,440 thousand at the end of 2023.

• Cash flow for the year was SEK -30,030 thousand, compared to SEK -31,551 thousand in 2023.

Outlook and guidance

• From 2025, interim reports will only be published for the first half and full year; no Q1 or Q3 reports.

• Board will only pursue investments or acquisitions if conditions are favorable; otherwise, a shareholder dividend is possible.